Form 4: Petros Pharmaceuticals Executive Fady Boctor Receives 450,000 Shares of Restricted Stock

Fady Boctor, a principal officer at Petros Pharmaceuticals, was granted 450,000 shares of restricted common stock on February 19, 2025, under the company's incentive plan.

Summary

• On February 19, 2025, Fady Boctor, a Principal President & Chief Commercial Officer of Petros Pharmaceuticals, acquired 450,000 shares of common stock.
• These shares were granted as restricted stock under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan.
• The shares vest in two tranches: 50% on the first anniversary of the grant date and the remaining 50% on the second anniversary, contingent upon continued service to the Issuer.
• Following the transaction, Boctor's total beneficial ownership in Petros Pharmaceuticals common stock is 499,645 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. The vesting schedule promotes long-term alignment.

Positives

• The grant of restricted stock aligns the executive's interests with those of the shareholders, incentivizing continued service and performance.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the incentive plan suggests a focus on long-term growth and value creation.

Industry Context

Grants of restricted stock are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock grants are a common form of executive compensation across the pharmaceutical industry.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedule of 1-2 years is fairly standard, aligning with typical performance evaluation cycles.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns executive interests with long-term value creation.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Petros Pharmaceuticals, Fady Boctor, restricted stock, beneficial ownership, Form 4, incentive plan, vesting